ALKS Q1 2024 Earnings — Alkermes plc Revenue & Financial Results | Market Cap Arena

ALKSAlkermes plc

$5B

Q1 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$350M+21.8% YoY

Gross Profit

$292M83.3% margin

Operating Income

$43M12.4% margin

Net Income

$37M10.5% margin

EPS (Diluted)

$0.21

QoQ Revenue Growth

-7.2%

Cash Flow

Operating Cash Flow

$21M

Free Cash Flow

$13M

Stock-Based Comp.

$33M

Balance Sheet

Total Assets

$2.1B

Total Liabilities

$869M

Stockholders' Equity

$1.3B

Cash & Equivalents

$421M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$350M	$288M	+21.8%
Gross Profit	$292M	$229M	+27.2%
Operating Income	$43M	-$11M	+494.7%
Net Income	$37M	-$42M	+188.0%

Revenue Segments

Product

$234M50%

Vivitrol

$98M21%

Aristada And Aristada Initio

$79M17%

L Y B A L V I

$57M12%